SCHEMBL3561679

SCHEMBL3561679

FC(F)(F)c1cc(-c2ccc(Cl)c(Cl)c2)nc(-n2cnc(Br)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
ALDH1A1 P00352 9/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 5/20 0.40
MAPT P10636 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 5/20 0.40
MAPK1 P28482 4/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 2/20 0.39
TP53 P04637 1/20 0.39
KIF20B Q96Q89 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562138 0.90 KDM4E (0.42) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3564984 0.88 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3559710 0.86 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3565787 0.84 KDM4E (0.46) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3562553 0.83 KDM4E (0.41) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3564669 0.82 SMN1; SMN2 (0.40) KDM4ESMN1; SMN2ALDH1A1KMT2AHPGD
SCHEMBL3565314 0.82 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3559991 0.81 KDM4E (0.42) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3559601 0.81 ALDH1A1 (0.43) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1
SCHEMBL3562958 0.81 PTGS2 (0.49) KDM4ESMN1; SMN2ALDH1A1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KDM4E 2568/4885SMN1; SMN2 980/4885ALDH1A1 1138/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KDM4E 1276/4885SMN1; SMN2 1177/4885ALDH1A1 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.